Comparing imaging techniques for diagnosing tumors in children and young adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate and compare the effectiveness of whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and PET/Computed Tomography (CT) imaging in diagnosing tumors in pediatric and young adult patients. The study will assess the sensitivities, specificities, and diagnostic accuracies of these imaging modalities to identify significant differences in their performance. Participants will include those with confirmed solid tumors or suspected solid tumors, and the study will collect data for analysis in an image registry.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor.
* We might also include some patients with leukemia if there is concern for a focal lesion in any of their organs.
* Participant's parents (if participant is under 18) or the participant (if participant is 18 years or older) must willingly give written informed consent prior to any image transfer to the image registry.

Exclusion Criteria:

* Patient has contraindications for MRI or PET/MR. This includes patients with cardiac pacemakers or intracranial vascular clips as well as patients with a blood glucose level \> 200 mg/dl.
* Lack of parental permission (if participant is younger than 18) or lack of informed consent (if participant is at least 18 years of age).
* Patient has a CNS primary tumor.
* Pregnant women and fetuses

Where it's running

• Stanford University, School of Medicine
  Palo Alto, California, United States Recruiting

Study contacts

• Principal investigator: Heike Daldrup-Link, MD — Stanford University
• Study coordinator: Anne Muehe
• Email: amuehe@stanford.edu
• Phone: 650-720-8601

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Using GnRHa to protect fertility during chemotherapy for young women

  This study is testing if a hormone treatment can help young women keep their ability to have children while they undergo chemotherapy for cancer.

  Recruiting at 4 sites Phase 3 Karolinska University Hospital · Gothenburg and 16 other locations · NCT05328258

• LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma

  This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.

  Recruiting Phase 1 Leukos Biotech S.L. · Barcelona, Barcelona · NCT07914348

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse

  A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Aarhus and 76 other locations · NCT07871864

• Immunotherapy plus standard treatment for high-risk osteosarcoma in kids and young adults

  This study tests mifamurtide added to standard chemotherapy versus standard treatment with sorafenib to see if the combination helps patients with high-risk osteosarcoma.

  Recruiting Phase 2 Institute of Mother and Child, Warsaw, Poland · Warsaw, Mazovian · NCT07787429

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.